Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)

Trial Profile

Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs ADX 102 (Primary)
  • Indications Sjogren-Larsson syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 09 Aug 2016 Results published in an Aldeyra Therapeutics Media Release
    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 According to an Aldeyra Therapeutics media release, the company has announced that thae last patient has completed dosing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top